摘要
目的观察盐酸埃克替尼治疗老年晚期非小细胞肺癌的近期疗效及安全性。方法回顾性分析老年晚期非小细胞肺癌患者24例，均口服单药盐酸埃克替尼，每次125mg，每日3次，直至病情进展或出现无法耐受的不良反应。观察近期疗效及不良反应。结果全组24例患者中无完全缓解患者，部分缓解6例，病情稳定11例，病情进展7例，客观缓解率25．0％（6／24），疾病控制率70．8％（17／24）；24例患者中有14例（58．3％）口服盐酸埃克替尼后有不同程度的症状缓解，咳嗽、胸闷、气喘症状改善最为明显。安全性方面，皮疹发生率20．8％，腹泻发生率12．5％，为Ⅰ～Ⅱ级不良反应；无患者因无法耐受药物不良反应而停药。结论盐酸埃克替尼单药治疗老年晚期非小细胞肺癌有较好的近期疗效，安全性好，值得临床进一步研究。
Objective To observe the efficacy and safety of icotinib hydrochloride in treatment of elderly patients with advanced non-small-cell lung cancer （NSCLC）. Methods Twenty-four elderly patients with advanced NSCLC were treated with icotinib hydrochloride（ 125 mg t. i. d）. The clinical data were retrospectively analyzed. Results Six patients （25.0%） showed partial response （PR）, 11 patients achieved stable disease （SD）, and 7 had progressive disease （PD） with a disease control rate （DCR） of 70.8% （17/24）. Fourteen patients （58.3%） achieved remission of symptoms to varying degrees. The main symptoms relieved were cough, asthmatic suffocating. The major adverse events were mild skin rash （20.8%） and diarrhea （12.5%） ,mainly in grade 1 - 2. There was no patient withdrawal from this study for safety consideration. Conclusion Monotherapy with icotinib hydroehloride is effective and tolerable for elderly patients with advanced NSCLC, which is worthwile for further study.
出处
《实用肿瘤杂志》
CAS
2014年第3期259-262,共4页
Journal of Practical Oncology
关键词
癌
非小细胞肺
药物疗法
肺肿瘤
药物疗法
酶抑制剂
治疗应用
受体
表皮生长因子
拮抗剂和抑制剂
回顾性研究
carcinoma, non-small-cell lung/drug therapy
lung neoplasms/drug therapy
enzyme inhibitors/ therapeutic use
receptor, epidermal growth factor/antagonists ＆ inhibitors
retrospective studies
